NCT00624312 2021-08-06
Procrit Versus Placebo to Determine Efficacy in Pre-Operative Major Surgical Oncology Operations
University of Louisville
Phase 2 Withdrawn
Clinical Trials
22 trialsNCT00495378 2016-12-20
RAPID-2. A Study to Evaluate the Effectiveness of Alternate Dosing of PROCRIT (Epoetin Alfa) in Maintaining Hemoglobin Levels in Patients With Chemotherapy Related Anemia
Ortho Biotech Products, L.P.
Phase 4 Terminated
NCT00267007 2014-06-04
A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT00386152 2013-07-19
A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Terminated
NCT01394991 2012-04-05
A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related Anemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 4 Completed
NCT00210587 2011-06-10
An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or Radiation
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00210730 2011-06-10
The Duration Study
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00337948 2011-06-10
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00338416 2011-06-10
An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00341055 2011-06-10
A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00269984 2011-06-08
A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00261677 2011-05-23
A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy
Ortho Biotech Products, L.P.
Phase 3 Completed
NCT00216541 2011-05-19
A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving Chemotherapy
Janssen-Cilag B.V.
Phase 4 Completed
NCT00350090 2011-05-19
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy.
Ortho Biotech Products, L.P.
Phase 3 Terminated
NCT00266617 2011-05-18
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00269997 2011-05-18
A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy Drug
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00270049 2011-05-18
Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic Leukemia
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2 Completed
NCT00270101 2011-05-18
The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00270127 2011-05-18
Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00270166 2011-05-18
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT00083434 2011-04-27
Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or Radiotherapy
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Terminated
NCT00283465 2011-01-14
A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing Chemotherapy
Janssen-Cilag B.V.
Phase 4 Completed